<SEC-DOCUMENT>0001213809-19-000027.txt : 20190508
<SEC-HEADER>0001213809-19-000027.hdr.sgml : 20190508
<ACCEPTANCE-DATETIME>20190508162625
ACCESSION NUMBER:		0001213809-19-000027
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20190507
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190508
DATE AS OF CHANGE:		20190508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYADIC INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001213809
		STANDARD INDUSTRIAL CLASSIFICATION:	INDUSTRIAL ORGANIC CHEMICALS [2860]
		IRS NUMBER:				450486747
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32513
		FILM NUMBER:		19806980

	BUSINESS ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		561-743-8333

	MAIL ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCP WORLDWIDE INC
		DATE OF NAME CHANGE:	20030110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8-kseruminstituteofindia.htm
<DESCRIPTION>8-K SERUM
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sbf9db40ab2854e198e0ea87a849192a8"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:center;-sec-extract:summary;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:144%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.2109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:33%;"></td><td style="width:34%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:144%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.2109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:33%;"></td><td style="width:34%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the </font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Report (date of earliest event reported): </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">May 7, 2019</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.2109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:33%;"></td><td style="width:34%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:144%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">Dyadic International, Inc.</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.2109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:33%;"></td><td style="width:34%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.2109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:33%;"></td><td style="width:34%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div><div style="padding-top:2px;text-align:center;padding-left:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(State or other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">000-55264</font></div><div style="padding-top:2px;text-align:center;padding-left:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Commission File Number)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">45-0486747</font></div><div style="padding-top:2px;text-align:center;padding-left:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(I.R.S. Employer Identification Number)</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">140 Intracoastal Pointe Drive, Suite 400</font></div><div style="padding-top:2px;text-align:center;padding-left:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Jupiter, FL 33477</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Address of principal executive offices and zip code)</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(561) 743-8333</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Registrant's telephone number, including area code)</font></div></td></tr><tr><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;(Former Name or Former Address, if Changed Since Last Report)</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.3828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Emerging growth company &#9744;</font></div><div style="padding-top:8px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:37%;"></td><td style="width:25%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title of each class</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trading Symbol(s)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name of each exchange on which registered</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Stock, par value $0.001 per share</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DYAI</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The NASDAQ Stock Market LLC</font></div></td></tr></table></div></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.01 Entry into a Material Definitive Agreement</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 7, 2019, Dyadic International, Inc. (&#8220;Dyadic&#8221; or the &#8220;Company&#8221;) entered into a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (&#8220;Serum&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of this collaboration, Serum anticipates applying Dyadic&#8217;s C1 technology to express up to twelve (12) antibodies and vaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic&#8217;s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sub-license for each of the twelve (12) proteins in return for certain research funding, milestone payments and royalties for 15 years from the date of the first commercial sale.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing description of the research and commercialization collaboration is qualified in its entirety by reference to the complete terms and conditions of the agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 8, 2019, Dyadic issued a press release announcing the entry into a research and commercialization collaboration in Item 1.01 on this Current Report on Form 8-K. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01 Financial Statements and Exhibits</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Exhibits</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:3%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a101serumresearchandcommer.htm"><font style="font-family:inherit;font-size:10pt;">Research and Commercialization Collaboration Agreement with Serum Institute of India Pvt,. Ltd., dated May 7, 2019</font></a><font style="font-family:inherit;font-size:10pt;">.  Specific items in this exhibit have been redacted, as marked by three asterisks [***].</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a991prserum.htm"><font style="font-family:inherit;font-size:10pt;">Press Release issued by Dyadic International, Inc. Announcing a Research and Commercialization Collaboration with Serum</font></a></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50%;"></td><td style="width:7%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dyadic International, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 8, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Mark A. Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark A. Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a101serumresearchandcommer.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBF945764CBD1B17391D193D5294AB8C1"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark &#8220;[***]&#8221;.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:right;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;text-decoration:underline;">Research and Commercialization Work Plan</font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;text-decoration:underline;">EXECUTION COPY</font></div><div style="line-height:138%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">The Development and Commercialization of Recombinant Vaccines and Therapeutic Proteins Using Dyadic&#8217;s C1 Fungal Expression System as the Commercial Production Platform </font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Introduction</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:28px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Serum Institute of India Private Limited, a Company incorporated under the Laws of India and having its registered address at 212/2 Off Soli Poonawalla Road, Pune 411028 (Serum) and Dyadic have agreed to enter into a commercial collaboration for 12 product candidates to be expressed using Dyadic&#8217;s C1 Technology through the definitive Collaboration Agreement for the development and commercialization of recombinant vaccines and therapeutic proteins using dyadic&#8217;s C1 fungal expression system as the commercial production platform.</font><font style="font-family:inherit;font-size:14pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;">Serum will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic&#8217;s C1 technology. [***]. Initially, through Phases I &amp; II below Dyadic will [***] costs incurred by Dyadic from its third party research collaborator &#8220;The VTT Technical Research Center of Finland&#8221;. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The purpose of the Dyadic/Serum Collaboration is to apply Dyadic&#8217;s C1 technology to express up to twelve proteins - 8 MABs and 4 rVaccines. In addition, Serum is also interested in developing [***].  Inclusion [***] in the Serum-Dyadic collaboration portfolio will be communicated and dealt separately. Serum will provide the gene sequences to Dyadic/VTT, which the Parties will need to agree upon in writing prior to the start of the project, which will be used for the expression and production of the Serum therapeutic and vaccine proteins using the C1 production platform. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">The specific goals of the collaboration are:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:28px;"><font style="font-family:inherit;font-size:11pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">For Dyadic to further develop/modify initial C1 strains to express up to twelve Serum proteins using the C1 gene expression platform of Dyadic. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:28px;"><font style="font-family:inherit;font-size:11pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">For Serum to bear the full cost of the development and commercialization of all twelve (12) of the proteins expressed from C1 in this collaboration and to conduct the necessary and required preclinical research and clinical trials and to file the required applications with the Indian FDA to begin with and other regulatory authorities including US FDA to allow the commercialization and marketing of the&#160;twelve (12) vaccines or drugs produced from Dyadic&#8217;s C1 gene expression platform.  It is further agreed that the new strains developed by Dyadic will be exclusively licensed to Serum and Dyadic cannot license, transfer, dispose off them to any third party including Danisco.</font></div></td></tr></table><div style="line-height:138%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In order to fulfill this goal:</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:96px;"><font style="font-family:Wingdings;font-size:11pt;">&#167;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Serum agrees to conduct all the necessary and required protein analysis and characterization in order to evaluate the quality of each of the expressed proteins. Serum also agrees to use its best efforts to develop and commercialize all twelve (12) of the proteins expressed from C1 in this project and to take all twelve (12) of these proteins through all the necessary and required preclinical research and clinical trials to prove that each of the chosen vaccines and/or&#160;drugs&#160;are safe and effective in treating a condition(s), and to file the required applications with the Indian FDA to begin with and other regulatory authorities including US FDA  to allow the marketing of the&#160;twelve (12)) vaccines and/or drugs produced from Dyadic&#8217;s C1 gene expression platform.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:96px;"><font style="font-family:Wingdings;font-size:11pt;">&#167;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Provided both parties fulfill their respective obligations including that the C1 modified strains pass all the requisite criteria as required by Serum, then Dyadic shall grant Serum the option to obtain an exclusive commercial sublicense(s) to all twelve (12) of the specific developed/modified C1 strains expressing the selected Serum proteins from this collaboration.  Each of the twelve (12) commercial sublicense(s) will be exclusive and shall be negotiated in good faith between Serum and Dyadic based on the projected commercial market for each of the selected proteins , provided that the financial obligations of Serum shall not exceed   the terms and conditions  of royalties &amp; project costs as prescribed in this Research and Commercialization Work Plan.  It is further agreed that Dyadic cannot transfer or dispose of the developed/modified C1 strains expressing the selected Serum proteins to any third party, including Danisco. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:96px;"><font style="font-family:Wingdings;font-size:11pt;">&#167;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Each sublicense will provide for royalties of [***] upon commercial sale of each of the products for a period of 15 years from the date of first commercial sale.  The Parties agree that such other terms &amp; conditions (other than the royalty rates) will be on reasonable commercial terms and conditions and will be subject to each of the Party&#8217;s other restrictions from third parties, if any. The terms and conditions of said sublicense(s) shall be negotiated in good faith by both Parties. Each commercial sublicense(s) option may be exercised by Serum by giving written notice to Dyadic following the conclusion of Phase I of the research below and such option shall be valid for a period of twelve months.&#160;Furthermore, Serum agrees to pay Dyadic a Milestone of [***] on 2nd&#160;anniversary of MA and an additional Milestone of [***] on 5th&#160;anniversary of MA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:96px;"><font style="font-family:Wingdings;font-size:11pt;">&#167;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;[***]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic/VTT will conduct the initial work to carry out Phase I and Phase II below at the VTT Technical Research Center of Finland. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:28px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In order to carry out the Phase I and Phase II Research Serum will provide Dyadic/VTT (i) information about the proteins (ii) the amino acid sequences of the target proteins (iii) a minimum of 2 mg of each protein to be used as a standard and (iv) purification methods, suggested by Serum that can be applicable by Dyadic/VTT, in case Protein A purification method cannot be applied.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Dyadic/VTT Work Plan</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:44px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:20px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The R&amp;D work will be done in two phases as follows:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:justify;padding-left:28px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">2.1 Phase I &#8211; First expression and production of Serum&#8217;s proteins at 1L scale</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">1)</font></div></td><td style="vertical-align:top;padding-left:30px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-30px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Step 1 - Studying protease activity against the target proteins</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:30px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">[***]</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">2)</font></div></td><td style="vertical-align:top;padding-left:30px;"><div style="line-height:138%;text-align:left;font-size:11pt;text-indent:-30px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Step 2 -Design and constructing the expression vectors </font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:30px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">[***]</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">3)</font></div></td><td style="vertical-align:top;padding-left:30px;"><div style="line-height:138%;text-align:left;font-size:11pt;text-indent:-30px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Step 3 - First set of proteins expression</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:30px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">[***]</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">4)</font></div></td><td style="vertical-align:top;padding-left:30px;"><div style="line-height:138%;text-align:left;font-size:11pt;text-indent:-30px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Step 4 - Laboratory scale fermentations</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">[***]</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">b.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Purified samples of the target proteins, if successful, will be delivered to Serum for further analysis and characterization. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;padding-left:28px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">2.2 Phase II &#8211; Second expression and production of Serum&#8217;s proteins at 1L scale</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:18px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">5)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Step 5 - Second set protein expression</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[***]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:18px;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">6)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Step 6 - Second set laboratory scale fermentation</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[***]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Samples of the target proteins will be delivered to Serum for further analysis and characterization. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:28px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Project timeline</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The total duration of the project is 10 months excluding the time needed for gene synthesis by a gene synthesis company. Although these are projected timelines, Dyadic will try to deliver the proteins from Phase I at the earliest.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:11pt;"><img src="siipldyadicts04052019_image1.gif" alt="siipldyadicts04052019_image1.gif" style="height:192px;width:530px;"><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:28px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Progress/Interim Meetings and Final Report:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:42px;"><font style="font-family:inherit;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Frequency of teleconferences and/or face-to-face meetings:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Throughout the project timeline monthly teleconferences or face to face meetings at VTT will be held between the project teams.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:left;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:42px;"><font style="font-family:inherit;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Reports to be provided to Serum Project Manager: </font><font style="font-family:inherit;font-size:11pt;">At the end of the project timeline, Dyadic will provide a written summary of the findings in the form of a Serum slide deck summarizing key outcomes (in PowerPoint format). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:28px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Final Materials Deliverables</font></div></td></tr></table><div style="line-height:138%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">At the end of the development project if successful</font><font style="font-family:inherit;font-size:9pt;">, </font><font style="font-family:inherit;font-size:11pt;">Dyadic will provide Serum with small samples of available proteins for further analysis</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:28px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Project resources</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic will provide all scientific and technical support as is required for this successful collaboration.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Project cost: </font></div></td></tr></table><div style="line-height:138%;padding-bottom:4px;padding-top:4px;text-align:justify;padding-left:120px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[***]</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Payments: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">For phase I, serum will pay to Dyadic 50% on signing of this Research and Commercialization Work Plan and 50% at the completion of Phase I.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">For Phase II, Serum will pay to Dyadic 50% on the starting date of phase II and 50% at the completion of phase II.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Serum shall make the payments subject to deduction of with-holding taxes, if any as may be applicable from time to time. Dyadic shall provide necessary document such as </font><font style="font-family:inherit;font-size:12pt;">IRS Tax Residency Certificate in Form 6166, &#8216;No permanent establishment&#8217; letter and Form 10F on letterhead that may be reasonably necessary</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">in order for Serum to support concessional or No withholding taxes as per the Double Taxation Avoidance Agreement between India and US.&#160;&#160;&#160;If the relevant supporting documentation is not provided by Dyadic within a reasonable timeframe following Serum&#8217;s request, the Serum shall deduct withholding tax at the applicable rate under tax legislations in India and shall provide a certificate of such deductions to Dyadic to claim credit of taxes in US.</font></div></td></tr></table><div style="line-height:138%;padding-bottom:4px;padding-top:4px;text-align:justify;padding-left:120px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Dyadic R&amp;D Point of Contact: </font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Ronen Tchelet</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic International (USA), Inc.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">140 Intracoastal Pointe Drive</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Suite # 404</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Jupiter, Florida 33477 USA</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel: + 36 30 864 6060</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Email: rtchelet@dyadic.com</font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Copy: mjones@dyadic.com</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Serum point of contact:</font></div><div style="line-height:240%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[***]</font></div><div style="line-height:240%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">212/2 Off Soli Poonawalla Road</font></div><div style="line-height:240%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Hadapsar, Pune 411028</font></div><div style="line-height:240%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">INDIA.</font></div><div style="line-height:240%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tel&#160;: </font><font style="font-family:inherit;font-size:11pt;">[***]</font></div><div style="line-height:240%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Email:</font><font style="font-family:inherit;font-size:12pt;color:#18376a;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:11pt;">[***]</font></div><div style="line-height:138%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF,</font><font style="font-family:inherit;font-size:11pt;">&#32;duly-authorized representatives of the parties have signed as of the Effective Date.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">DYADIC INTERNATIONAL (USA), INC. ( DYADIC)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">SERUM INSTITUTE OF INDIA PVT. LTD. (SERUM)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Mark A Emalfarb</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/Adar C. Poonawalla</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Printed Name: Mark A. Emalfarb</font></div><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Chief Executive Officer</font></div><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date:  </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">5-7-2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Printed Name:  Adar C. Poonawalla</font></div><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Chief Executive Officer</font></div><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">6th May 2019</font></div></td></tr></table></div></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>a991prserum.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s36c3aad95c2c449e9492fc9ab94b6085"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 99.1</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><img src="image0a09.jpg" alt="image0a09.jpg" style="height:60px;width:76px;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Dyadic and&#160;Serum Institute&#160;of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products and Vaccines</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PUNE, INDIA / JUPITER, FLORIDA / ACCESSWIRE / May 8, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;- Dyadic International, Inc. (&#8220;Dyadic&#8221;) (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, is pleased to announce a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (&#8220;Serum&#8221;), one of the world's largest vaccine manufacturers, to develop and manufacture up to twelve antibodies and vaccines using Dyadic&#8217;s C1 gene expression platform. This important collaboration is focused on making biologic vaccines &amp; drugs accessible and more affordable to patients worldwide while lowering the financial burden on the global healthcare system. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the terms of this collaboration, Serum anticipates applying Dyadic&#8217;s C1 technology to express up to twelve proteins - 8 MABs and 4 rVaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic&#8217;s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sublicense for each of the twelve (12) proteins in return for certain research funding, milestone payments and royalties for 15 years from the date of the first commercial sale.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#32;&#8220;We are very excited to collaborate with Serum as our philosophies are directly aligned. Our goal is to offer our C1 gene expression platform to biotech and pharmaceutical companies as well as renowned institutes and governmental agencies that are committed to reducing the cost of healthcare and saving lives. Serum is a Worldwide leading vaccine and drug development institution and we are excited by the science and results we believe we can achieve together&#8221;, said Mark Emalfarb, Dyadic&#8217;s CEO. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8220;Serum has a proven track record of more than 50 years of developing and delivering affordable vaccines and drugs globally and we are eager to incorporate Dyadic&#8217;s industrially proven C1 gene expression platform into our antibody and vaccine development and manufacturing programs&#8221; said Adar Poonawalla, CEO, Serum Institute of India. He further stated that &#8220;In recent years, monoclonal antibodies have emerged as preferred therapeutic candidates for the treatment of a multitude of disorders and diseases. These include a broad range of cancers, auto-immune diseases, microbial infections. Traditionally, antibody treatment is extremely costly and not widely affordable in the developed and developing worlds. We at Serum are committed to finding ways to speed the development, lower the cost and improve the performance of high quality, affordable antibodies and vaccines which have the potential to treat and prevent various diseases in India and across the globe. Dyadic&#8217;s C1 gene expression platform has the potential to help us deliver on our commitment to bring down the cost of biologics in order to make them more accessible and affordable to patients globally.&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8220;This collaboration will further demonstrate the potential of C1 to become a platform of choice for manufacturing protein-based biologics and vaccines because of its speed of development and low cost of goods.&#8221; said Matthew Jones, Dyadic&#8217;s CCO. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">About Serum Institute </font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Serum Institute of India Pvt. Ltd. is the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by Serum are accredited by the World Health Organization, Geneva and are being used in approximately 170 countries across the globe in their national immunization programs, saving millions of lives.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Serum is ranked as India's No.1 biotechnology company, manufacturing highly specialized lifesaving biologics like vaccines using cutting edge genetic and cell-based technologies, antisera and other medical specialties.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 99.1</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Serum was founded in 1966 by Dr. Cyrus Poonawalla with a mission of manufacturing life-saving immuno-biologics, which were in short supply in India and were being imported at extremely high prices. Thereafter, several life-saving biologics were manufactured by Serum with the result that the country became self-sufficient for Tetanus Anti-toxin and Anti-snake Venom serum, followed by the DTP (Diphtheria, Tetanus and Pertussis) group of Vaccines and then later with the MMR (Measles, Mumps and Rubella) group of vaccines.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The philanthropic philosophy of Serum continues with its work on newer vaccines such as Rotavirus vaccine, Meningitis A vaccine and other combination vaccines.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Learn more about Serum Institute of India at https://www.seruminstitute.com/ </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">About Dyadic International, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Additionally, and more recently, Dyadic is also beginning to explore the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated&#160;viral vectors&#160;(AAV), certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Please visit Dyadic&#8217;s website at </font><font style="font-family:Arial;font-size:10pt;color:#0000ff;text-decoration:underline;">www.dyadic.com</font><font style="font-family:Arial;font-size:10pt;color:#0000ff;">&#32;</font><font style="font-family:Arial;font-size:10pt;">for additional information, including details regarding Dyadic&#8217;s plans for its biopharmaceutical business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Safe Harbor Regarding Forward-Looking Statements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;look forward to,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions. Forward-looking statements are based on management&#8217;s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic&#8217;s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic, political and market conditions; (2) our ability to generate the required productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) our ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic&#8217;s and third parties research and development efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on key customers and collaborators; (8) the pharmaceutical and biotech industry, governmental regulatory and other agencies&#8217; willingness to adopt, utilize and approve the use of the C1 gene expression platform; and (9) other factors discussed in Dyadic&#8217;s publicly available filings, including information set forth under the caption &#8220;Risk Factors&#8221; in our December&#160;31, 2018 Annual Report filed </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 99.1</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">with the SEC on the Form 10-K on March&#160;27, 2019. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Contact:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Dyadic International, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Mr. Mark Emalfarb, CEO</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Phone: +1 (561) 743-8333</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Email: </font><font style="font-family:Arial;font-size:11pt;color:#0000ff;text-decoration:underline;">memalfarb@dyadic.com</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Contact:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Serum Institute of India Pvt. Ltd.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Mr. Adar C. Poonawalla, CEO</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Phone: +91 20 2660 2501</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Email:&#160;</font><font style="font-family:Arial;font-size:11pt;color:#0000ff;text-decoration:underline;">acp@seruminstitute.com</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image0a09.jpg
<TEXT>
begin 644 image0a09.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1"617AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0=NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %!I;F<@4F%W
M<V]N   !ZAP !P  " P   AH     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M.AZ:GR_XVUT^)?&VJZKN+1SW#>3GM&ORI_XZ!6%2=*ZSQOX-E\)6^@R2 _\
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MKXAUS_D8M2_Z^Y?_ $,U&&W8ZNQ[?^S7_P @_P 0_P#7:#_T%Z]OKQ#]FO\
MY!_B'_KM!_Z"]>WUE6_B,N'PH*^4?C;;+;_%G4R@P)4AD./4QJ#^HKZNKY9^
M.Y!^*MT!VMH0?^^:K#_&*I\(_P" MTT'Q2AB4X%Q:S1M[@ -_P"RUTO[2?\
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M_"%^*/\ H7=5_P# .3_"OKZBCZNNX?VI/^4^-M0T'5])B675-+O+*-VVJ]Q
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M>M?]<X__ $:E14^!FV'_ (T/5?F?+%(>AI:0]#7F'UI]D^'O^19TO_KSB_\
M0!6C6=X>_P"19TO_ *\XO_0!6C7J1^%'Q\_B844451 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DO[0?_ "*FE_\ 7[_[
M(U> 5[_^T'_R*FE_]?O_ +(U> 5Y];^(SZ7+_P#=U\S7\)_\CIHO_7_!_P"C
M!7V%7Q[X3_Y'31?^O^#_ -&"OL*ML/U.+-/BB%%%%=1XX5QOQ:_Y)7K7_7./
M_P!&I795QOQ:_P"25ZU_USC_ /1J5%3X&;8?^-#U7YGRQ2'H:6D/0UYA]:?9
M/A[_ )%G2_\ KSB_] %:-9WA[_D6=+_Z\XO_ $ 5HUZD?A1\?/XF%%%%40%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y+^
MT'_R*FE_]?O_ +(U> 5[_P#M!_\ (J:7_P!?O_LC5X!7GUOXC/I<O_W=?,U_
M"?\ R.FB_P#7_!_Z,%?85?'OA/\ Y'31?^O^#_T8*^PJVP_4XLT^*(4445U'
MCA7&_%K_ ))7K7_7./\ ]&I795QOQ:_Y)7K7_7./_P!&I45/@9MA_P"-#U7Y
MGRQ2'H:6D/0UYA]:?9/A[_D6=+_Z\XO_ $ 5HUG>'O\ D6=+_P"O.+_T 5HU
MZD?A1\?/XF%%%%40%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!Y+^T'_P BII?_ %^_^R-7@%>__M!_\BII?_7[_P"R-7@%
M>?6_B,^ER_\ W=?,U_"?_(Z:+_U_P?\ HP5]A5\>^$_^1TT7_K_@_P#1@K["
MK;#]3BS3XHA11174>.%<;\6O^25ZU_USC_\ 1J5V5<;\6O\ DE>M?]<X_P#T
M:E14^!FV'_C0]5^9\L4AZ&EI#T->8?6GV3X>_P"19TO_ *\XO_0!6C6=X>_Y
M%G2_^O.+_P! %:->I'X4?'S^)A1115$!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 >2_M!?\BII?_7[_P"R-7@%?5?Q#\#G
MQWI-K9+?_8?L\_F[S%YF[Y2,8R/6O/O^&=G_ .AE7_P"_P#LZXJM.<IMI'N8
M/%4:=%1F[,\L\)_\CIHO_7_!_P"C!7V%7CFD? 5]+UJROSXA$OV6X2;9]CQN
MVL#C._CI7L=:T82C>YRX^M3JRBX.X4445T'FA7&_%K_DE>M?]<X__1J5V58W
MB[0#XH\*WNC"X^S&Z55\W9OVX8-TR,]/6IFFXM(UHR4:D9/9-'Q_2'H:]K_X
M9W?_ *&5?_ +_P"SH/[.SX_Y&5?_  "_^SK@]C/L?1?7L/\ S?F>O>'O^19T
MO_KSB_\ 0!6C5;3K3[!I=K:;]_V>%(MV,;MJ@9Q^%6:]".B1\U)WDV@HHHID
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>siipldyadicts04052019_image1.gif
<TEXT>
begin 644 siipldyadicts04052019_image1.gif
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M_4A0U9\$5?WV14'54E]9U,GL+$'5[;??/MJT:=-H__WW7W'CMNNNNXX.//#
MT5%''34NYPTWW+ #9 &UAMY)TH"0/&\W&>NE>^ZY9\=UQ+?<<HN5,J%NN^VV
M977(WVT3H=6(-IL?(X>M7+>\#'WU2:64FOL;3D'53.O=R65_\PM!53\25/4G
M056_?5%0M=17%O&D9PFJKK_^^M$^^^RSXH:MB_N*3A)4K=\ GSQO _V\#-[K
M#:K235'??5(II>;^AE-0-=-Z=W+9W_Q"4-6/!%7]SV,$5<.=@^^4]PV+>-*S
M!%4;-VY<%:2:%U"U>?/F\2"6?,PQQWAW/A)4]=4N\[:WVCJFS>;'H$W'FR)!
ME5)*K6YR)JB:3;T[N>QO?B&HZD>"JO[G,8*JX<[!=\K[AD4\Z5F!J@@K6.9W
M\LDGCZZ^^NKQ8'7333>-MFS9,B[?P0<?/)>@2G6[]H*J^6R7@BJEE%K;Y$Q0
M-9MZ=W+9W_Q"4-7O/9F@JK]YC*#*.7BO?6413WI6H.J,,\Y8]KE'''%$=3O*
M^( '/&#%]GF2YU>^\I7+_BX-U#$Q=-J&Q.U LD,//73<>>D(Z;W820XZZ* =
M^]<2OE]YY97C]T\XX83Q\5*.K7PBG\XK)JDF63M1+.QWV&&'C=\CCU>N;=NV
M[3@VVU#V5);:<3F?4E)XWD_'PJ]YS6O&D+"T3RH_2S;9+NW#,<@[==YYYRT[
M%O5YXHDGCC_KWGOOW9%</M;I'GOLL2+Q=_K"*AV7<R:O64SL3<XDMN6]5(?)
MM!=>I^Z2@**\=OCAAR\K\_'''S\Z_?33Q^?/YU.W9YYYYO@ZYL<[]=136Y/^
M3UHF1%T!:4\ZZ:3QN:;MV?_7?_W7QVV==EAKESBV TP>J_@:GU42D5.\3QGY
M[....VY'>TK[<MUJ?3*5-__LDK9NW;JL/'G$EE)*":H$58(J096@2E EJ!)4
M":H$5;V!JOBY (*F@;?-&S9L6/9WZ0LFYMM)L&KWW7<O'A,8$SM);D!%29Q+
M:?M\8(CG!0AAHE_:CSQ>*>$X8*.T#>< $*I%N<3ZYKSB:\F[[;;;#E 1R\_K
M1+_EK[_UK6]MS35&LOPWOO&-G9=V<EV -6W'/?;88W<D\6ZZ5KD!4P"?+MNR
M'?51>Y_W@$)=!]FF,G$>P+/2@P4F=:G?H/WVVV_9:]1Q%/ J]J>\/:VF/+3O
MDF*TY 477. ,5BDEJ!)4":H$58(J096@2E EJ!)4]0^JF)#&&S4FK6>===8X
M:B-%>JPGJ"+:IP:I<@#4! .BB!R)(*<+J&HK!Q"+R7Y;6>-Q:J"J!B+RI9A$
M%D5@5H(V][G/?3I=HR;@$_V6M[RE6H_1@$':2U<HM!ZN0<M)RO0?_L-_:&T'
M:P55E#."OBBBG)IRPZVF/#R],PKX&B/KB&!32BE!E:!*4"6H$E0)J@15@BI!
ME:"J=U#%<K:X="A"#<KR[&<_>[S4J6F9$68B/"FHBI$K*4\6 Q#+M6+T"=YS
MSST;(U+./??<ZCDU@:HTX+'D#%@7/YNR/>A!#UH!F]B6\E+N$MBI@:JX/P C
M0I)]]]VW"@4!'"]^\8M'/_$3/['B'*@[CLFQ]]IKKQ7[MBW](VKL@0]\X J@
MDJ+*6"H7(ZWX+);* 1^Y)OF2//8[Y913&N%+ B2T2Y9NQH@KZI9K0]03VW*=
M\_KF_VG)9*ZF,M4BVO)CLC_[4I_ W:<][6FCQS[VL9V6_I5 %67(R\TU3Q%I
M2=1U4UUU6?J'XS6*2QQC&:DGI9025 FJ!%6"*D&5H$I0):@25 FJ9O;4O](R
MLMJ$/8*+F+BYM*RO#53MLLLNC?L 'F+YGOK4IR[[F[Q%N6K+_MI %4 G!QGD
M@6JK%Y:)Y0+63 *JXOY-D"U?HI:@#D JOG_===<M.^:EEUZZ8IMWO.,=C9%I
M,7(,"!ES*0%OVB)VHFC;I7,JY9F*RS!+$(77\FV 2I.J5B9,_99$U%Z7P;L$
MJA!MMO8Y7-L<6,8^DO>[MF3J\3K&,L9E?[$]*J64H$I0):@25 FJ!%6"*D&5
MH$I0U2NH0DQ.21@]Z5*B:8"J+L B@B>BB/)E<X"LM%]<]O=3/_53G4$54411
M31!OX\:-*[8',L1]:J"*")S2_DW+\_)S120X[])V8E35RU[VLD90%2$1[8/S
MR$UT4RP?]8\!=I0M)<=/KD7P 6;X3$ 3<(4V&;<E7UDL0UP:6:K3U"XF+5,;
M>%L+J(KP,,\/%^'C0Q_ZT%6#*B*U\O.C;:4' \1E?UU HU)*":H$58(J096@
M2E EJ!)4":H$5;T) ,+2)F !$*8MTFH]0%773L(RNU)^HAB1]((7O* SJ(KG
M4]JF2V?MFDR=)[)UV;\)Q,3ZK)4I;A?!9!SHVZY3S;_S.[\S41ZL:1L@%P6@
M6DV9V@;CM8 JHM/R97GTM;2L,EZ;QS_^\:L&58C^7$JJ'I=B-B6D5THI096@
M2E EJ!)4":H$58(J096@:N8"7,4E2NL)JIBL=^TD,<\/N:[B\7G_;6][V[J!
MJAIHBGF!FI[Z-RFHB@/;>H&JN"1LM292JBEZZ1&/>,34854N<EU-6J8^0%6I
M/0"*8D0@UR5>NTE!%<MG2[ SS[$%R..SE5)*4"6H$E0)J@15@BI!E6.)H$I0
M-3-0%7,.E10GN4V3X@@_B'J*:GO275J6E"LN0TN=!% 4\_R4EJNM%Z@J+95B
MLM\U1U5IZ2#7I.FI<W%@BTFW\R5D3><1!YXXT),'*R92YTNAR4<>>>0*(!*O
M9PEF\L5(KC0B?"A7K<X!.6UEB#<',8<5=1X3E]?@:5L_7"NHBDOOJ*^8W)Q(
MP;6"JM+UC$_\C'G>E%)*4"6H$E0)J@15@BI!E:!*4"6HZAU4T5F 0$T#:AH(
M2F:975-C9G*<"QC1%@W#,JT(?B*X29V$)YC%2)G\;SYO/4%5Z8F#Y+GJ"JI*
M3ZF[^.*+&S\O#FPQ>3N1,6D)61+YGN)QWOK6MS8NF8O+PFJYGW+ ]J0G/:DQ
MH@YH%:]1Z2:$8\6<6K4<8O'X\4NV+<JO5*;<M;Y!&6-[!^9- JI*<#=O;VDY
MX"2@*O;)I)CX/D:1Q7:LE%*"*D&5H$I0):@25 FJ!%6"*D'53$!5^DR6J]'X
MR%^3$E63O+JV+ KOM]]^R[8O01J !X,)D2(E(/#8QSYV!6SB6 R6+-LJ/9$M
M[R1$R-1R%9&8?-J@*B:VIKQ$[1#Y4ELFV?34/Y8L<IXIJBA&G$5@$P<V0$N\
M1M09$(_(H:U;MXX_(UZWSWSF,\5Z3=<2X!'S.I&X/"X/X\F(7&..^;C'/6Y%
MQ%F*J.+?&!F7X$Z,<+KVVFN+;05P YA+3SQ$_)_ZXQI0#_$:QFN21WGQ;XPT
M*BT3I(US?2@G3U3D?#DNUSQNRVNI#CF/-E#5!&\3Z&T"5?$]KG7>)_/$^[$=
MY'V_2W2E4DH)J@15@BI!E:!*4"6H$E0)J@15O8&J:?A][WM?:P+V$OQHVR>^
MGW>2N-POF032I7-<*Z@B$JFIO("F"(YJH*HIDB?YA2]\82.H0C&!?%M=INB9
MIF68G'>,ULK?P['\AQQR2/%ZLVVZ[K6DYI2%[6)^KUH;2F6H/6&QJ7UT+5-;
M9%N,Z(LN@<DH %'M.O!DP#90%6%94T08 *NT36F)KE)*":H$58(J096@2E E
MJ!)4":H$5;V#*H!%%UB2_.I7O[HQR3:#1BFJ*E^Z55J*!1"IP1\B5V(>IKR3
M$%%3FN@3^;(>H(IS)+]/J=[8E@BCN ^PI'2=.:^89ROWZ:>?OF*?VL#6Y<EV
M #26%B;Q_]H^:>"?Y(EY1#4U)=\''D[Z-,&]]]Z[\9C1^?DE35HFMF^*),RO
M0\R!-2FH0D0N-D4Y-8$JHKSRI.A-H(IM2^<U3S<F2BDEJ!)4.;D45 FJ!%6"
M*D&5H&HG!E4)] "LB*I@J1'+@U*T"J8L3*19QH28/!/IP?8TUMQ &@28 6BE
M8W#<-&@3 9+OD\ "T2D @OQS@21\'A%#^3XQ#P]EJ24I9UE8OB^?GP."_#VV
M+4&$TCFRI(H(%2+"@!V<,W6)(]A)QZT]]8]]&;#R^DI13]1/K?Q1E(EE:7G=
M8Q*LLU\I43TYD%B6"7#)/X?SCL?E./EQ6=K'-0.H)3#(]:)>N'YI._(PI>B@
M=/V//OKH<3F?^]SGKB@ORPBI \J5RDS[HTQ<VWQ;_N8:T"9B;JZDKF7*VR2?
MR^=3COSS@$(GG'#">$EE$FTW'B,=)[Y6$GG*XG8Q:JJIG:8^"0BN]<DDVFH7
M\*F44H(J096@2E EJ!)4":H$58(J0=5,0-7.H+CT+29DGS;8RW,DM94%:)5R
M,-5 E5)]":A8BO932JF%N^$45,VTWIU<]C>_$%3U(T%5?Q)4]=L7G;LN]95%
M/&E!U>I%Q @1./GRME+DT+3$(,Y20ZX93]-+T(JH&")?:D\H+%UG097J4T2E
MY3G T@,'E%)J(6\X!54SK7<GE_W-+P15_4A0U9\$5?WV1>>N2WUE$4]:4+7V
M&\S\*8/K*0;QKOF26$:9/R5/4*6&U%=8VJB44HZ-@JI9U+N3R_[F%X*J?B2H
MZD^"JG[[HG/7I;ZRB"<MJ)K.Y)L<2BD!]7JI*Z@B=Q.YG9JNLZ!*S:JOT#[7
MNZ\HI=0\C8V"JG[KW<EE?_,+054_$E3U)T%5OWW1N>M27UG$DQ9432XZ>#*3
M;G+M]#7Q)G$XT2@D\0:.I7+0>7F=98 EQ>3:,2F\4GWU%:646G0)JF9;[TXN
M^YM?"*KZD:"J/PFJ^NV+@JJEOK*()RVH4DHII93J?W(FJ)I-O3NY[&]^(:CJ
M1X*J_B2HZK<O"JJ6^LHBGK2@2BFEE%*J_\F9H&HV]>[DLK_YA:"J'PFJ^I.@
MJM^^**A:ZBN+>-*"*J644DJI_B=G@JK9U+N3R_[F%X*J?B2HZD^"JG[[HJ!J
MJ:\LXDD+JI122BFE^I^<":IF4^].+ON;7PBJ^I&@JC\)JOKMBX*JI;ZRB"<M
MJ%)**:64ZG]R)JB:3;T[N>QO?B&HZD>"JOXDJ.JW+PJJEOK*(IZTH$HII912
MJO_)F:!J-O7NY+*_^86@JA\)JOJ3H*K?OBBH6NHKBWC2@BJEE%)*J?XG9X*J
MV=2[D\O^YA>"JGXDJ.I/@JI^^Z*@:JFO+.))1U"U<>/&<0?46FNMM=;3=P15
M!SW_M\>P:EZ<ROW.<]XWE_4^3V7>M&G3C]K(00?-5;G3)/.PPPZ;JW)3WC0I
MGJ=R;]BP85SNM[_][7/9)\\___RY*3-U3)FI<\>2]?/11Q^]['OR-W_S-T=W
MW777Z.Z[[Q94+2JH.N"  U;<0&FMM=9:Z_7Q@S8\SGK06FNMEWSPP0<O^_NT
MTTX;;=^^?73CC3<*JA855!UXX('C4$:MM=9::SU]QQORO1[[Q-&_VF/#W#B5
M>\.&O>>RWN>IS'OMM=>XS+OMMMM<E7N//?88EWOWW7>?JW)37LI-^>>IW+ON
MNNN.*)]Y[)/[[+//W)0Y1:]1YXXEZ^=G/.,9R[XG_^M__:]C2/7E+W]94+6H
MH,H<54HII912ZWC#:8ZJF=;[/,D<5?W*'%6SZ9/FJ'(LJ?5%<U0M]95%/&E!
ME5)**:54_Y,S0=5LZMW)97_S"T%5/Q)4]2=!5;]]45"UU%<6\:0%54HII912
M_4_.!%6SJ7<GE_W-+P15_4A0U9\$5?WV14'54E]9Q),65"FEE%)*]3\Y$U3-
MIMZ=7/8WOQ!4]2-!57\25/7;%P552WUE$4]:4*644DHIU?_D3% UFWIW<MG?
M_$)0U8\$5?U)4-5O7Q14+?6513QI09522BFE5/^3,T'5;.K=R65_\PM!53\2
M5/4G056_?5%0M=17%O&D!55**:644OU/S@15LZEW)Y?]S2\$5?U(4-6?!%7]
M]D5!U5)?6<23%E0II9122O4_.1-4S:;>G5SV-[\05/4C055_$E3UVQ<%54M]
M91%/6E"EE%)**=7_Y$Q0-9MZ=W+9W_Q"4-6/!%7]25#5;U\45"WUE44\:4&5
M4DHII53_DS-!U6SJW<EE?_,+054_$E3U)T%5OWU14+745Q;QI&<)JAB4:I[E
M0)_[EEMN6=@.L7GSYF5U<<PQQW3:[YY[[AEMV[9M/" F<ZR;;KK)V4F/:NI?
M0^IS0[BY&TJ?Y[/S:W+;;;>U[G/OO?>NN)9WWGFG'4"I.9B<":IF4^].+ON;
M7PBJ^KN7$53U(T%5OWU14+745Q;QI&<)JN*-6O0>>^PQ.NB@@T8GG'#"Z,HK
MKYQ)F19Y I\&M.2V@>WZZZ\?PZS==MNM>DWWVV^_T2FGG#*8B?2UUUX[[@/)
MG/,0=<899RPK)^5>:_^*=L(X^SY_U%%'+2O+@0<>.'$_7>]SB'V&MJF46MNX
M(ZCJM]Z=7/8WOQ!4]2-!57\25/7;%P552WUE$4]ZR* J^M!##UWW@4Q059\
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ME:!*4"6H$E0)J@15@JIU U4);,2)Z$,>\I#1K_S*K[0N9V)"E"(@2L"KS?G
M&2,=8EZ8F @YF63P<9+;9:E.US(RR8Y J:FL3!P3**CEE0*H <J:0!63R+@?
MD\HNZIK3"D!0&JRH:\K3M!_P9#7+2]L, ,TGWM&E+X#8S])DGOXVC3*5!N\N
MH J8$&$C "5_/\*0>![ D:9^<?GEEZ\ )<#$N.VO_=JO-2;B3P"*=HNX#NMQ
M??,^#PB/8T_)M'O@2"G:J$M?C(KC10Z@<H 8CP<H0XPI7>HRAVR<:UQVN%I_
M^M.?;NR?^3B3'I01WZ.-Q'YVW_O>=^)KJ)2@2E EJ!)4":H$58(J096@2E U
M=5"%F#RW34Z8<-/YXL22B?;99Y^](@J 233;\V]M,IH&3B(B5CMI:P,R?'9I
M*5&,]DINFSAW 4#GG'-.ZT0V'B<.;$R&XSX)(C2IM%^*PBF]SO*F.%AUJ?/[
MW>]^*YZ@ENIPSSWW7/7U;*NW+J#J:4][6A5> @N:0-AJ014P)>9CPJ]\Y2M'
M/_F3/[FL[A(\B/WN9W[F9R9N:T<???0*0-)E/]H#=1DC>-CW?_VO_[7B.N37
MMQ1QP_:,;ZG/UZ!,ZO-77WUUL9SL5WJ=^BT]@:_- **HN*2/.HMC1,P-EY8(
MT@=K=1GKA?,@<HGK7;LFW(A-\J"$]#U2JO]2G7-NU/FD_2Q%Q&'&_GQ[0942
M5 FJ!%6"*D&5H$I0):@25 FJUAU4E9Z&E4]H\H&9Y20Q"N0I3WG*LK^)1H@J
M12BD@3-.\(!'V[9M&[]'9 R3U*9)%1-C)KX<KY1\O+2TAX@FHI:BF(P2I=46
MJ4"=\7G\&\'' 0<<L*(.$V0B,J0$!N/ 5CJ/4GES<>P(VJB;M R)NF097"Q;
MA!UI^1L3;,ZQ%*'3E) ZU<M__(__<074C+F;:I-W8 +7C>5&DX*JF',J1<WD
MR[%X: #G_?K7OW[9DM%2OJG2 P8F 0LQ&I#R 5!R0,%UBP E78?4GTI+=6M1
M,%QGOC0__.$/CQ[P@ <L>X^E:?FRW=C6?O9G?[8:!5;[@DO]-1?U5NOS\3RX
M!O1A!#2BC''?U[WN=<6^2-_BN-1I[(L<)XI^$.$0R^AR1;!+FZ!<L:W0]O.Z
MC.6FO<;QDC(2D9C@&/O_^9__^>C?_MM_NR+2DL_+VV)\'Z>ENH@^$\> 6C1J
MWL\>^M"'+@-O<7D?Q^?S&1MGD7M0*4&5H,K)I:!*4"6H<BP15 FJ%@Q4U8!!
M;:(7HPKR24Y:;E=*+%R:M)9RQL0H".!8+0J&25E,^!LGDY,^J:LTP6Z*;(J3
MTS@)3DOL<L6HB#BPE:*<VA(;,]F.Y8A?3BSUC-$4L2RE_4KYLG(H4IJ\=LG#
M58I.R8]56M;7UL_B^5&^+C<@Z_74/\H7X6=L(X"]4L10@C=-D*4$Y9)8KA8C
M96+?!)@T19D!BF/2[W@^.7AIZ_.E9:VE:,$8%1>!>)>^6+MAB, 6(-HT'@(+
M&9?:$K&WU66JJ[8;G5HR];CDK]2VX[+-4GN)_2SO XRI)?"HE*!*4"6H$E0)
MJ@15@BI!E:!*4-4;J(H3L!B10^/-'2=YN^RR2W%Y&-$@3 ") N!7^]*DM017
M2I"K%E55RB\3)W.E<T])G $PDRP%8Q+7=IW;8$,7 %.*NFK[HHGY>CBWDF+]
MQ"5GI=P^)*YNF_P""&GC0 P&[#_ZHS^:&%01X3%)/76I_[8ED], 50 @CE,R
MX( (E=IRQ!21%B$%QRRI+?=6'GE'4NUXC6)_QK$/W.<^]RE>7\8#KB\YKTI]
M/B7=;NKSI:6^)<@5^\##'_[P%9%)<:SHTEY0+ -E3S".AQ"4^E&,/.M:EQ&B
M-CW5L U4Q6/G#S?H"MHQ[:*I?^=)\XG((FJK%"FKE*!*4"6H$E0)J@15@BI!
ME:!*4+4NH"I.9E?C4MZ:+DEYNSZ.O99'J71>;: *<+3:Q,9,W**8Q$V:?+@M
MVJB4S+KV=+):'=4&R[C=(Q[QB-;!*NX#S&JKJY_XB9^8&%3%FX!I@*K2TKUI
M@ZHN^["4L@2X$FR);:(V7I2@0@VD1NC2U<][WO-:MRD!ZM7T>:)[2HH)^V.?
M+8T57:+X$+ H+I&CSY5>3S!HTEQNM>5V76YT:MMW;7=MY8AC"9&M78 ]$-*G
M_BE!E:!*4"6H$E0)J@15@BI!E:!J74$5$[,FR$340"U2)/<--]PP!C9-3S'K
M,FEELC3)Y'PUH"HN8TN/LV=B3'E*N8*:)KYM29Y+N:7B)#P>EZ4W799AK@94
MQ9PU^^Z[[\2@BCHE$H](MZX1:>L%JDIY>]KR)\T"5-6B A,(B>V(B,228MZN
M)K 1H^RX5EWZ,U%H7%^B)]NN;\S)-JT^'P'P-$%5">(Q/L=\?7FD55SNV*4N
M(_2J0;EI@BI 4MMU*-UL<VT88THYWIIRTBDEJ!)4":H$58(J096@2E EJ!)4
M30U4$<E12[3;M+2D34R4^(6>21\3GUI.'0;.4I0)^\9RUIY:MQI0%8^1GL*6
M5,J;M19055IZ%B>]I>/&"6-ZBEA-I65>)<4GO470T!54Y0+&$:4!Y*N!S]6
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M)5$5Y6(Z_IPHY4HSM.+GD,YQFZ9ERB(BBBI%E:)*4:6H4E0IJA15BJJ!BBI
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M%LF2)4MJQ0$//Z4!><R-=BQ)&3Y+F_']%%MG.]KYQAMO+&[+]Q%)6B11Q7E
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
